Let me first state that the obvious motivation behind the short piece was to drive down the sp. They're using scare tactics and invalid facts which IMO takes away from any credibility the "analysis" has. That being said, there are definitely a few things they mention that should be addressed by management, period.
- What is the relationship and arrangement with Cognate. What exactly are we paying for and why does it seem to be so excessive in comparison to other similar trials. Nobody can possibly make a well informed case that the relationship is a good thing for shareholders without the details.
- This is the first I have seen about technology transfers to Dennis M. Is this true? If so why?
- Why has screening been suspended and what has the company done to date to rectify? What is their estimate for when this screening halt will be lifted?
- What is going on with Direct? The company laid out unrealistic timelines for start, data, completion, and start of Phase II that have not been met. Why?
- What is going on with HE and EA programs? Once again the company was quick to PR the benefits this had but has failed to keep shareholders informed of what is gong on?
Call me a short, dismiss my concerns all you like, but this type of information matters to me and a lot of investors that like to make well informed decisions and mitigate as much risk as possible from an already risky sector. I don't have to sell and I don't want to sell. I have followed the guidance of this Management Team for years, they were the ones that laid out false expectations that kept me invested. They should be the ones to clarify the points so that I can make a decision, not me having to sell and move on.
News 
Market Data 
Discover 
AI
